The Impact of Time Restricted Feeding in Crohn's Disease
Condition: Crohn's Disease (CD) Intervention: Other: Time Restricted Feeding Sponsors: Weill Medical College of Cornell University; The Kenneth Rainin Foundation Recruiting
CONCLUSIONS: SBS can be safely and effectively treated with EBD using BAE, thus reducing the need for surgery in the long term. PMID: 32216446 [PubMed - as supplied by publisher]
CONCLUSIONS: The correlation between increase of inflammatory markers and increased risk of osteoporotic fractures and the lack of difference between Crohn's disease and ulcerative colitis suggest a central role of inflammation over malabsorption in this population. PMID: 32218426 [PubMed - as supplied by publisher]
Publication date: Available online 28 March 2020Source: Pathology - Research and PracticeAuthor(s): Biljana Stankovic, Sanja Dragasevic, Kristel Klaassen, Nikola Kotur, Sanja Srzentic Drazilov, Branka Zukic, Aleksandra Sokic Milutinovic, Tamara Milovanovic, Snezana Lukic, Dragan Popovic, Sonja Pavlovic, Gordana Nikcevic
In conclusion, reduced DJ-1 expression promotes inflammation and IEC apoptosis via p53 in colitis, suggesting that the modulation of DJ-1 expression may be a potential therapeutic strategy for managing colitis.
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application. Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain. As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn's...
(The Mount Sinai Hospital / Mount Sinai School of Medicine) In a series of four studies published today in Gastroenterology, a journal of the American Gastroenterological Association, Mount Sinai inflammatory bowel disease (IBD) researchers, describe the identification of predictive tools and a new understanding of environmental factors that trigger IBD.
(Scripps Research Institute) The US Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis. The drug is also in advanced clinical development for adults and children with moderate-to-severe ulcerative colitis and Crohn's disease.
Condition: Crohn Disease in Remission Interventions: Other: Faecal calprotectin (FC); Other: quantitative Faecal Immunochemical Testing (qFIT); Other: Serum and faecal zinc Sponsor: NHS Greater Glasgow and Clyde Not yet recruiting
This study extended the clinical utility of a previously validated clinical decision support tool for predicting treatment effectiveness of vedolizumab in Crohn's disease.Alimentary Pharmacology &Therapeutics